Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

ent granting agency to Dr. Kim Chi, a medical oncologist at the BC Cancer Agency and Research Scientist at the Vancouver Prostate Centre.
  • We continue to accrue patients in a Phase 1 clinical trial evaluating OGX-427 infusion into the bladder prior to surgical removal of all or part of the bladder. This study, also grant funded, is sponsored by the National Cancer Institute of Canada (NCIC).
  • Financial Results Under our Collaboration Agreement with Teva relating to our contribution to the custirsen Phase 3 development plan, we earned Collaboration Revenues of $4.9 million and $11.3 million, respectively, for the three and nine months ended September 30, 2010, compared to no revenues in the corresponding periods of 2009. Of the revenues in the third quarter, $3.5 million is reimbursable from Teva on a cash basis and is included on the Company's balance sheet as amounts receivable at September 30, 2010. As of September 30, 2010, $23 million of the upfront payment received from Teva was included on the Company's balance sheet as deferred collaboration revenue which we are amortizing over the expected performance period of our deliverables under our agreement. We currently expect this performance period to end in the fourth quarter of 2012.

    Research and development expenses for the three and nine months ended September 30, 2010 were $6.7 million and $16.2 million, respectively, compared to $1.5 million and $6.3 million, respectively, in the corresponding periods of 2009. The increased research and development expenses recorded in the three and nine months ended September 30, 2010 are the result of increased expenses relating to OncoGenex's contribution to the custirsen Phase 3 clinical trials and increased employee expenses.

    General and administrative expenses for the three and nine months ended September 30, 2010 were $1.1 million and $3.9 million, respectively, compared to $0.9 million and $2.7 million, respectively, in the co
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
    2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
    3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
    4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
    5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
    6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
    7. OncoGenex Reports Second Quarter Financial Results
    8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
    9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
    10. OncoGenex Reports First Quarter Financial Results
    11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
    (Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
    (Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
    (Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
    Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
    ... zinc oxide (ZnO) are among the most technologically ... in optoelectronic elements such as blue lasers (hence ... also finds many uses in optoelectronics and sensors. ... made of these materials have shown a plethora ...
    ... Cell Assurance, Inc. (Pink Sheets: SCLZ) announced ... the Alexandria Innovation Center in Jupiter, Florida to open its ... Assurance represents an integral step for the Company to begin ... with developing potential cellular treatment protocols, stem cell based IP, ...
    ... developing a new class of "plasmonic metamaterials" as ... ultrapowerful microscopes and computers, improved solar cells, and ... could make possible "nanophotonic" devices for numerous applications, ... and computer engineering at Purdue University. Unlike ...
    Cached Biology Technology:Nanowires exhibit giant piezoelectricity 2Nanowires exhibit giant piezoelectricity 3Stem Cell Assurance to Open New Laboratory Facility in Jupiter, Florida 2New materials may bring advanced optical technologies, cloaking 2
    (Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
    (Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
    (Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
    Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
    ... Illinois at Champaign-Urbana have found that people employed in ... Uganda are exchanging gastrointestinal bacteria ?specifically Escherichia coli ?with ... strains migrating to chimps are resistant to antibiotics used ... appear in the April 2007 issue of Biological Conservation ...
    ... Researchers from Biotech Research & Innovation Centre (BRIC) at University ... regulate the function of stem cells. The results are published ... including human beings, consist of a number of specialised cell ... cell; the embryonic stem cell. Stem cells can develop into ...
    ... for improved study of hepatitis C virus by devising ... patient-isolated virus in nontransformed hepatocytes, instead of culture-adapted virus ... by Lázaro et al, "Hepatitis C virus replication in ... the February issue of The American Journal of Pathology. ...
    Cached Biology News:E. coli bacteria migrating between humans, chimps in Ugandan park 2E. coli bacteria migrating between humans, chimps in Ugandan park 3New culture method for hepatitis C virus uses primary hepatocytes and patient serum 2
    ... number is a new product number, ... number. If showing no availability yet, ... number (C6671) or contact customer service ... Surface area 148 cm 2 ...
    ... Detection System is intended for use in ... by an in-house validated in vitro nucleic ... interest. • The ... hybridization capture assay designed to detect amplified ...
    ... System is optimized for maximum packaging efficiencies of ... bacteriophage l vector. Using a test insert with ... arms (> 4 x 10^8 pfu/g ligated l ... is extremely easy to use; simply add up ...
    BD BioCoat Laminin 150 mm Culture Dishes...
    Biology Products: